Key publications

H.M.G. Barriga*, I.J. Pence*, M.N. Holme, J.J. Doutch, J. Penders, V. Nele, M.R. Thomas, M. Carroni, M.M. Stevens, Dynamic degradation of bioactive lipid nanoparticles by phospholipase D, Advanced Materials 2022, 34 (26)

T. Sych, J. Schlegel, H.M.G Barriga, M. Ojansivu, L. Hanke, F. Weber, R. Beklem Bostancioglu, K. Ezzat, H. Stangl, B. Plochberger, J. Laurencikiene, S. El Andaloussi, D. Fürth, M.M. Stevens, E. Sezgin, High-throughput measurement of the content and properties of nano-sized bioparticles with single-particle profiler, Nature Biotechnology 2024, 42, 587–590

J.P. Bost, H.M.G. Barriga, M.N. Holme, A. Gallud, M. Maugeri, D. Gupta, T. Lehto, H. Valadi, E. K. Esbjorner, M.M. Stevens, S. El-Andaloussi, Delivery of oligonucleotide therapeutics: Chemical modifications, lipid nanoparticles, and extracellular vesicles, ACS Nano 2021, 15, 9, 13993–14021

H.M.G. Barriga, M.N. Holme, M.M. Stevens, Cubosomes: The Next Generation of Smart Lipid Nanoparticles? Angew Chem Int Ed Engl. 2019, 58(10), 2958–2978

Precision Nanomedicine Engineering for Personalised Medicine

The group uses a multidisciplinary approach that combines biology, physics and chemistry to advance our understanding of nanoscale structure and dynamics in biological processes. We aim to use this information to accelerate the development of the next generation of engineered nanomedicines.

The group has three key focus areas (A) nanoscale engineering (B) improved disease understanding and (C) performance validation. By combining large datasets with single particle analysis, we use this information to improve our understanding of how disease impacts the performance of nanomedicines to attempt to engineer improved delivery technologies on the nanoscale.

An important part of this research is utilisation of large scale research infrastructure including X rays, neutrons and Cryo EM. This enables characterisation of nanoscale structures which is key to providing mechanistic explanations and enabling us to map the relationship between nanoscale structure and performance.

Our long term goal is to use these multidisciplinary datasets to enable the rational design of nanomedicines for specific diseases and patients.

Where can you find us?

The group is part of the Division of NanoBiotechnology within the Department of Protein Science and we are located at SciLifeLab in Solna.

Last updated: 2024-08-28

Content Responsible: Hampus Persson(hampus.persson@scilifelab.uu.se)